{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T02:00:00Z","timestamp":1769306400950,"version":"3.49.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T00:00:00Z","timestamp":1574294400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T00:00:00Z","timestamp":1574294400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1038\/s41409-019-0754-3","type":"journal-article","created":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T15:03:40Z","timestamp":1574348620000},"page":"483-484","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Is this real life? Is this just fantasy? Decreased relapse following haploidentical transplant in Hodgkin\u2019s lymphoma with posttransplant cyclophosphamide"],"prefix":"10.1038","volume":"55","author":[{"given":"A","family":"Mussetti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Sureda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,11,21]]},"reference":[{"key":"754_CR1","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","volume":"30","author":"A Younes","year":"2012","unstructured":"Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma. J Clin Oncol. 2012;30:2183\u20139.","journal-title":"J Clin Oncol"},{"key":"754_CR2","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1411087","volume":"372","author":"SM Ansell","year":"2015","unstructured":"Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma. N Engl J Med. 2015;372:311\u20139.","journal-title":"N Engl J Med"},{"key":"754_CR3","doi-asserted-by":"publisher","unstructured":"Rivas MM, Berro M, Prates MV. Allogeneic stem cell transplantation improves survival in relapsed Hodgkin lymphoma patients achieving complete remission after salvage treatment. Bone Marrow Transpl. 2019. https:\/\/doi.org\/10.1038\/s41409-019-0640-z [Epub ahead of print].","DOI":"10.1038\/s41409-019-0640-z"},{"key":"754_CR4","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/j.bbmt.2008.08.014","volume":"14","author":"LM Burroughs","year":"2008","unstructured":"Burroughs LM, O\u2019Donnell PV, Sandmaier BM, Storer BE, Luznik L, Symons HJ. et al. Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory hodgkin lymphoma. Biol Blood Marrow Transpl. 2008;14:1279\u201387.","journal-title":"Biol Blood Marrow Transpl"},{"key":"754_CR5","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1016\/j.bbmt.2019.05.025","volume":"25","author":"S Ahmed","year":"2019","unstructured":"Ahmed S, Kanakry JA, Ahn KW, Litovich C, Abdel-Azim H, Aljurf M, et al. Lower graft-versus-host disease and relapse risk in post-transplant cyclophosphamide\u2013based haploidentical versus matched sibling donor reduced-intensity conditioning transplant for hodgkin lymphoma. Biol Blood Marrow Transpl. 2019;25:1859\u201368.","journal-title":"Biol Blood Marrow Transpl"},{"key":"754_CR6","doi-asserted-by":"crossref","unstructured":"Gauthier J, Poir\u00e9 X, Gac AC, Leclerc M, Guillaume T, Chalandon Y, et al. Better outcome with haploidentical over HLA-matched related donors in patients with Hodgkin\u2019s lymphoma undergoing allogeneic haematopoietic cell transplantation\u2014a study by the Francophone society of bone marrow transplantation and cellular therapy. Bone Marrow Transpl. 2018;53:400\u20139.","DOI":"10.1038\/s41409-017-0018-z"},{"key":"754_CR7","doi-asserted-by":"publisher","first-page":"230","DOI":"10.3324\/haematol.13441","volume":"94","author":"SP Robinson","year":"2009","unstructured":"Robinson SP, Sureda A, Canals C, Russell N, Caballero D, Bacigalupo A, et al. Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin\u2019s lymphoma: identification of prognostic factors predicting outcome. Haematologica. 2009;94:230\u20138.","journal-title":"Haematologica"},{"key":"754_CR8","doi-asserted-by":"publisher","unstructured":"De Philippis, C, Legrande, F, Bramant, S. Checkpoint inhibitor treatment before haploidentical transplantation in relapsed or refractory Hodgkin\u2019s lymphoma (HL) patients is associated with higher PFS without increased toxicities. EBMT. 2019. https:\/\/doi.org\/10.1038\/s41409-019-0561-x.","DOI":"10.1038\/s41409-019-0561-x"},{"key":"754_CR9","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1136\/bmj.2.5216.1837","volume":"2","author":"JQ Matthias","year":"1960","unstructured":"Matthias JQ, Misiewicz JJ, Scott RB. Cyclophosphamide in Hodgkin\u2019s disease and related disorders. Brit Med J. 1960;2:1837\u201340.","journal-title":"Brit Med J"},{"key":"754_CR10","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1182\/blood-2015-09-671834","volume":"127","author":"AS Kanate","year":"2016","unstructured":"Kanate AS, Mussetti A, Kharfan-Dabaja MA, Ahn KW, DiGilio A, Beitinjaneh A, Chhabra S, et al. Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors. Blood. 2016;127:938\u201347.","journal-title":"Blood"},{"key":"754_CR11","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1016\/j.bbmt.2019.05.017","volume":"25","author":"J Mariotti","year":"2019","unstructured":"Mariotti J, Devillier R, Bramanti S, Giordano L, Sarina B, Furst S, et al. Peripheral blood stem cells versus bone marrow for T cell\u2013replete haploidentical transplantation with post-transplant cyclophosphamide in Hodgkin lymphoma. Biol Blood Marrow Transpl. 2019;25:1810\u20137.","journal-title":"Biol Blood Marrow Transpl"},{"key":"754_CR12","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1126\/science.1068440","volume":"295","author":"L Ruggeri","year":"2002","unstructured":"Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295:2097\u2013100.","journal-title":"Science"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41409-019-0754-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-019-0754-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-019-0754-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:16:23Z","timestamp":1684617383000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-019-0754-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,21]]},"references-count":12,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["754"],"URL":"https:\/\/doi.org\/10.1038\/s41409-019-0754-3","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,21]]},"assertion":[{"value":"18 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}